Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
2.
Am J Pathol ; 191(5): 921-929, 2021 05.
Article En | MEDLINE | ID: mdl-33607042

Loss-of-function mutations in arachidonate lipoxygenase 12B (ALOX12B) are an important cause of autosomal recessive congenital ichthyosis (ARCI). 12R-lipoxygenase (12R-LOX), the protein product of ALOX12B, has been proposed to covalently bind the corneocyte lipid envelope (CLE) to the proteinaceous corneocyte envelope, thereby providing a scaffold for the assembly of barrier-providing, mature lipid lamellae. To test this hypothesis, an in-depth ultrastructural examination of CLEs was performed in ALOX12B-/- human and Alox12b-/- mouse epidermis, extracting samples with pyridine to distinguish covalently attached CLEs from unbound (ie, noncovalently bound) CLEs. ALOX12B--/- stratum corneum contained abundant pyridine-extractable (ie, unbound) CLEs, compared with normal stratum corneum. These unbound CLEs were associated with defective post-secretory lipid processing, and were specific to 12R-LOX deficiency, because they were not observed with deficiency of the related ARCI-associated proteins, patatin-like phospholipase 1 (Pnpla1) or abhydrolase domain containing 5 (Abhd5). These results suggest that 12R-LOX contributes specifically to CLE-corneocyte envelope cross-linking, which appears to be a prerequisite for post-secretory lipid processing, and provide insights into the pathogenesis of 12R-LOX deficiency in this subtype of ARCI, as well as other conditions that display a defective CLE.


Arachidonate 12-Lipoxygenase/genetics , Ichthyosis/diagnostic imaging , Lipid Metabolism , Proteins/metabolism , Animals , Arachidonate 12-Lipoxygenase/deficiency , Arachidonate 12-Lipoxygenase/metabolism , Epidermis/ultrastructure , Female , Humans , Keratinocytes/ultrastructure , Male , Mice , Mice, Knockout , Middle Aged , Mutation , Pyridines/metabolism , Skin/ultrastructure
3.
Methods Mol Biol ; 2248: 167-183, 2021.
Article En | MEDLINE | ID: mdl-33185875

Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal dysplasia, a congenital condition characterized by the absence or abnormal formation of sweat glands, teeth, and several skin appendages. Stimulation of the EDA receptor (EDAR) with agonists in the form of recombinant EDA or anti-EDAR antibodies can compensate for the absence of Eda in a mouse model of Eda deficiency, provided that agonists are administered in a timely manner during fetal development. Here we provide detailed protocols for the administration of EDAR agonists or antagonists, or other proteins, by the intravenous, intraperitoneal, and intra-amniotic routes as well as protocols to collect blood, to visualize sweat gland function, and to prepare skulls in mice.


Edar Receptor/metabolism , Signal Transduction/drug effects , Animals , Animals, Newborn , Disease Models, Animal , Drug Administration Routes , Ectodermal Dysplasia/drug therapy , Ectodermal Dysplasia/genetics , Ectodermal Dysplasia/metabolism , Edar Receptor/genetics , Mice , Phenotype , Recombinant Proteins/administration & dosage , Treatment Outcome
5.
J Mammary Gland Biol Neoplasia ; 23(3): 125-138, 2018 09.
Article En | MEDLINE | ID: mdl-29855766

Hypohidrotic ectodermal dysplasias (HED) are hereditary differentiation disorders of multiple ectodermal structures including the mammary gland. The X-linked form of HED (XLHED) is caused by a lack of the secreted signaling molecule ectodysplasin A1 (EDA1) which is encoded by the gene EDA and belongs to the tumor necrosis factor (TNF) superfamily. Although male patients (hemizygous) are usually more severely affected by XLHED, heterozygous female carriers of an EDA mutation may also suffer from a variety of symptoms, in particular from abnormal development of their breasts. In Tabby mice, a well-studied animal model of XLHED, EDA1 is absent. We investigated the effects of prenatal administration of Fc-EDA, a recombinant EDA1 replacement protein, on mammary gland development in female Tabby mice. Intra-amniotic delivery of Fc-EDA to fetal animals resulted later in improved breastfeeding and thus promoted the growth of their offspring. In detail, such treatment led to a normalization of the nipple shape (protrusion, tapering) that facilitated sucking. Mammary glands of treated female Tabby mice also showed internal changes, including enhanced branching morphogenesis and ductal elongation. Our findings indicate that EDA receptor stimulation during development has a stable impact on later stages of mammary gland differentiation, including lactation, but also show that intra-amniotic administration of an EDA1 replacement protein to fetal Tabby mice partially corrects the mammary gland phenotype in female adult animals.


Ectodermal Dysplasia 1, Anhidrotic/therapy , Mammary Glands, Animal/pathology , Animals , Breast/pathology , Breast Feeding/methods , Cell Differentiation/physiology , Disease Models, Animal , Ectodysplasins/genetics , Female , Fetal Therapies/methods , Immunoglobulin Fc Fragments/genetics , Lactation/genetics , Mice , Mice, Inbred C57BL , Morphogenesis/genetics , Morphogenesis/physiology , Mutation/genetics , Pregnancy , Recombinant Fusion Proteins/genetics , Signal Transduction/genetics , Signal Transduction/physiology
6.
N Engl J Med ; 378(17): 1604-1610, 2018 04 26.
Article En | MEDLINE | ID: mdl-29694819

Genetic deficiency of ectodysplasin A (EDA) causes X-linked hypohidrotic ectodermal dysplasia (XLHED), in which the development of sweat glands is irreversibly impaired, an condition that can lead to life-threatening hyperthermia. We observed normal development of mouse fetuses with Eda mutations after they had been exposed in utero to a recombinant protein that includes the receptor-binding domain of EDA. We administered this protein intraamniotically to two affected human twins at gestational weeks 26 and 31 and to a single affected human fetus at gestational week 26; the infants, born in week 33 (twins) and week 39 (singleton), were able to sweat normally, and XLHED-related illness had not developed by 14 to 22 months of age. (Funded by Edimer Pharmaceuticals and others.).


Antigens, CD/therapeutic use , Ectodermal Dysplasia 1, Anhidrotic/therapy , Ectodysplasins/genetics , Ectodysplasins/therapeutic use , Fetal Therapies/methods , Genetic Therapy/methods , Immunoglobulin Fc Fragments/therapeutic use , Prenatal Diagnosis , Receptors, Fc/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Adult , Amniotic Fluid , Ectodermal Dysplasia 1, Anhidrotic/diagnostic imaging , Ectodermal Dysplasia 1, Anhidrotic/genetics , Ectodysplasins/deficiency , Female , Humans , Injections , Male , Mutation , Pregnancy , Radiography , Recombinant Proteins/therapeutic use , Sweat Glands/abnormalities , Sweat Glands/diagnostic imaging , Tooth Germ/diagnostic imaging
7.
Sports Health ; 6(2): 136-8, 2014 Mar.
Article En | MEDLINE | ID: mdl-24587863

BACKGROUND: Head injuries are responsible for the majority of serious equestrian sports injuries and deaths. Because of significant health risks to equestrians, education regarding the prevention of head and brain injuries is essential. HYPOTHESIS: A significant number of riders have experienced a concussion, and few have knowledge of concussion. STUDY DESIGN: Cross-sectional study. LEVEL OF EVIDENCE: Level 2. METHODS: Ninety-four riders competing, riding, or attending equestrian events at the Palm Beach International Equestrian Center in Wellington, Florida, from January to April 2010 were surveyed. Measures of central tendency were utilized to evaluate response patterns. RESULTS: Almost half of equestrian riders (44%) experienced concussions during their careers. Those riders who suffered a brain injury were likely to return to riding without seeking medical clearance. Almost 40% of riders were never educated regarding concussions, while 15% received education from their trainers. CONCLUSION: Education of riders, parents, and horse trainers is needed to raise awareness of concussions and reduce the likelihood of subsequent injuries.

8.
J Invest Dermatol ; 133(1): 172-80, 2013 Jan.
Article En | MEDLINE | ID: mdl-22832496

Loss-of-function mutations in the lipoxygenase (LOX) genes ALOX12B and ALOXE3 are the second most common cause of autosomal recessive congenital ichthyosis. The encoded proteins, 12R-LOX and epidermal LOX-3 (eLOX-3), act in sequence to convert fatty acid substrates via R-hydroperoxides to specific epoxyalcohol derivatives and have been proposed to operate in the same metabolic pathway during epidermal barrier formation. Here, we show that eLOX-3 deficiency in mice results in early postnatal death, associated with similar but somewhat less severe barrier defects and morphological changes than reported earlier for the 12R-LOX-knockout mice. Skin lipid analysis demonstrated that the severity of barrier failure is related to the loss of covalently bound ceramides in both 12R-LOX- and eLOX-3-null mice, confirming a proposed functional linkage of the LOX pathway to ceramide processing and formation of the corneocyte lipid envelope. Furthermore, analysis of free oxygenated fatty acid metabolites revealed strongly reduced levels of hepoxilin metabolites in eLOX-3-deficient epidermis, indicating an additional function of eLOX-3 in mammalian skin as a hepoxilin synthase linked to the 12S-LOX pathway.


Arachidonate 12-Lipoxygenase/physiology , Epidermis/physiology , Intramolecular Oxidoreductases/physiology , Lipoxygenase/physiology , Animals , Arachidonate 12-Lipoxygenase/genetics , Ceramides/analysis , Ceramides/metabolism , Disease Models, Animal , Epidermis/chemistry , Epidermis/metabolism , Epidermis/pathology , Fatty Acids, Nonesterified/analysis , Fatty Acids, Nonesterified/metabolism , Ichthyosis/genetics , Ichthyosis/metabolism , Intramolecular Oxidoreductases/genetics , Lipids/analysis , Lipoxygenase/genetics , Mice , Mice, Knockout , Mutation , Severity of Illness Index
9.
Nurs Prax N Z ; 25(1): 17-26, 2009 Mar.
Article En | MEDLINE | ID: mdl-19558051

This paper reports the results of a project aimed at decreasing the use of, and costs associated with, the practice of using care assistants to provide one-to-one observation or 'specialling' in five acute adult medical and surgical wards at a North Island hospital. Education sessions were provided to staff to prompt better management of patients receiving this level of observation. Using a time-series design, a retrospective study was completed for the six months pre- and six months post-intervention (staff education). Data were collected and analysed on all patients in the five acute wards who had required 'specialling' during the specified twelve-month period. Results showed that following the intervention there had been a reduction in the incidence and duration of 'specialling,' and a halving of costs associated with this practice. The findings have implications for patient management and cost effectiveness. Incident statistics were not retrospectively reviewed in this study.


Nursing Assessment , Nursing Assistants/statistics & numerical data , Nursing Staff, Hospital/education , Personnel Staffing and Scheduling , Adolescent , Adult , Aged , Aged, 80 and over , Cost Control , Female , Hospital Costs , Humans , Male , Middle Aged , New Zealand , Personnel Staffing and Scheduling/economics , Retrospective Studies
...